A2b adenosine receptor regulates hyperlipidemia and atherosclerosis

Area of Science:

• Cardiovascular Science
• Metabolic Disease Research
• Pharmacology

Background:

• The cAMP-elevating A(2b) adenosine receptor (A(2b)AR) plays a role in inflammation through bone marrow cells.
• Its specific role in metabolic diseases and atherosclerosis was previously unclear.

Purpose of the Study:

• To investigate the role of the A(2b)AR in diet-induced hyperlipidemia and atherosclerosis.
• To determine the molecular mechanisms by which A(2b)AR influences liver lipid metabolism.

Main Methods:

• Utilized apolipoprotein E-deficient mice fed a high-fat diet to model atherosclerosis.
• Performed bone marrow transplantation, liver gene/protein expression analysis (Western blotting, qPCR), and primary hepatocyte studies.
• Employed adenoviral gene delivery and pharmacological A(2b)AR agonists/antagonists.

Main Results:

• A(2b)AR deficiency exacerbated atherosclerosis and led to elevated liver/plasma cholesterol and triglycerides, with fatty liver pathology.
• A(2b)AR deficiency increased hepatic expression of sterol regulatory element binding protein-1 (SREBP-1) and lipogenic enzymes.
• Restoring A(2b)AR in the liver or administering an A(2b)AR agonist reduced hyperlipidemia and atherosclerosis.

Conclusions:

• The A(2b)AR is a key regulator of liver SREBP-1, hyperlipidemia, and atherosclerosis.
• Targeting the A(2b)AR presents a potential therapeutic strategy for metabolic and cardiovascular diseases.